2026-02-26 - MDT - Medtronic Deep Dive

Article published Feb 26, 2026. Prices below use latest available snapshots.

MDT Price Structure

Loading chart…

Loading timeframes…

Conviction: Medium Status: Watching — RSI 36.3 entering oversold zone, price -2.4% in 7D, -2.0% in 30D

Quick Snapshot

Signal	Reading
Overall	🟡 RSI 36.3 — approaching oversold. Price $98.61, +1.8% today, -2.4% in 7 days, -2.0% in 30 days. Near 52wk high ($103.18). YTD +22% performance now slightly digesting.
Moat	Moderate-Wide — scale and switching costs, but execution has lagged peers
Key insight	MDT now has fresh OHLC data. RSI 36.3 suggests the post-Q3 enthusiasm is cooling and the stock is approaching an attractive entry zone. Sitting near 52wk high (-4.4%) after +22% YTD run — consolidation is healthy. PFA growth +80%, Hugo FDA cleared, MiniMed spinoff on track. Entry zone is $88-94; current $98.61 is above ideal but RSI approaching watch territory.

Action Matrix

Action	Level	Why
Current	🔍 Watch	RSI 36.3 approaching oversold — closer to entry zone. Alert at $92 still active.
Entry Zone	$88 - $94	~10-15% pullback from current ~$98; prior support zone
Stop-Loss	$79 (-20%)	Below 52-week low ($79.55) — thesis-killer territory
Target 1	$108 (+9%)	Return to consensus analyst target zone
Target 2	$117 (+19%)	All-time high (Sept 2021) — full recovery scenario

Extended analysis

Price Data

Stock	Price	1D	7D	30D	3M	52wkHi	RSI	Status	Action
MDT	$98.61	+1.8%	-2.4%	-2.0%	—	-4.4%	36	🟡 Approaching Oversold	🔍 Watch

Legend

52wkHi = -4.4% from $103.18 (52-week high in data window)
52wk Low = $79.55
All-Time High = $117.57 (September 8, 2021)
SMA20 = $100.61 (price is -2.0% below SMA — very close)
RSI trend: Declining from ~58 (post-Q3) toward 36 — healthy digestion

Price vs Last Deep Dive (02/22)

Metric	02/22	02/26	Change
Price	$97.58 (market data)	$98.61 (OHLC)	+$1.03 (+1.1%)
RSI	~58 (estimated)	36.3 (fresh data)	-21.7 (significant pullback in RSI)
SMA20	~$100 (estimated)	$100.61	Now have fresh SMA
vs SMA	~-3%	-2.0%	Very close to SMA

Update from 02/22: MDT now has fresh OHLC data. Price is $98.61, essentially flat from prior estimate ($97.58). RSI has dropped significantly — from an estimated ~58 to 36.3 — reflecting post-Q3 enthusiasm cooling. The stock is -2.0% below SMA20 ($100.61) — nearly at SMA. The -2.4% 7D and -2.0% 30D show digestion of the strong Q3 move. At $98.61 with RSI 36.3, MDT is getting closer to the entry zone but still above the ideal $88-94 level. Watch for continued RSI decline toward 30-35 as the re-entry signal.

Company Overview

One-Liner

Medtronic is the world's largest standalone medical device company by revenue — a $34B/year enterprise spanning heart rhythm management, surgical robotics, spinal implants, neurostimulation, and diabetes technology operating in 150+ countries.

Business Model

Question	Answer
What they sell	Implantable and non-implantable medical devices, capital equipment, disposables, software systems
Who pays	Hospitals, health systems, surgical centers, government payers — indirect (devices reimbursed via procedure codes)
Revenue model	Mix of capital equipment (upfront) + high-margin disposables/consumables (recurring), service contracts
How sticky	High — physician training on specific platforms creates lock-in; hospital systems make multi-year purchasing commitments

Key Segments (Q3 FY2026 — Quarter Ended January 23, 2026)

Segment	Q3 Revenue	Q3 Organic Growth	FY%	Key Products	Notes
Cardiovascular	$3.457B	+10.6%	~38%	PFA/Affera system, TAVR (Evolut), cardiac monitoring, cardiac surgery	Star segment — PFA +80% global, +137% US
Neuroscience	$2.558B	+2.5%	~28%	Spinal fusion/implants, neuro-stimulation, ENT, surgical navigation	Slowest growth; spine is structurally sluggish
Medical Surgical	$2.173B	+2.7%	~24%	Hugo surgical robot, endoscopy, respiratory care, renal care	Hugo FDA cleared Feb 2026 — early innings
Diabetes	$796M	+8.3%	~9%	MiniMed CGM, insulin pumps	Being spun off as MiniMed (mid-late 2026)

FY2026 YTD (9 months): Revenue run-rate approaching $34B; 6.0% organic in Q3 is highest in 10 quarters.

Investment Thesis

Bull Case — The Inflection Is Real

Argument	Evidence	Conviction
PFA is a genuine multi-year growth driver	Cardiac Ablation Solutions +80% global, +137% US in Q3 FY26. Affera (Sphere-9) offers dual-energy (PFA + RF) vs. BSX Farapulse (PFA-only).	🟢 High
MiniMed spinoff unlocks value and focus	Removing GLP-1 narrative overhang; 100+ bps margin uplift post-spinoff.	🟢 High
Hugo FDA clearance opens $13B+ robot market	Just cleared for urologic procedures Feb 2026. First US procedure at Cleveland Clinic.	🟡 Medium (early)
Dividend aristocrat with 48 years of increases	$2.84/year annual dividend (~2.9% yield at current price), supported by $3.3B+ in 9-month FCF.	🟢 High
Valuation is modest vs. peer group	MDT P/E ~26x forward — cheapest large-cap medtech. BSX trades at 57x. SYK at ~35x.	🟢 Medium-High
Tariff headwinds are quantified	MDT guided $185M tariff impact for FY26 — already priced into guidance.	🟢 High

Bear Case — The Value Trap Scenario

Argument	Evidence	Risk Level
10-year history of underperformance	MDT all-time high was Sept 2021 ($117.57). Still 16% below that.	🟠 Real
Too diversified to move the needle fast	$34B revenue spread across 4 segments means even 80% PFA growth is diluted.	🟡 Medium
Hugo is years from meaningful revenue	ISRG has 10,763+ installed systems. Hugo just got first FDA clearance Feb 2026.	🟠 Real
Neuroscience / Spine is a structural drag	Spine market mature, price-deflationary. MDT's neuro segment grew only 2.5% organically.	🟡 Medium

Financial Profile

Revenue Trajectory

Metric	FY2023	FY2024	FY2025	FY2026 Guidance
Revenue	~$31.2B	~$32.4B	$33.5B	~$35-36B (est.)
Organic Growth	~4%	~5%	~5%	~5.5% guided
Q3 FY26 Organic	—	—	—	6.0% (best in 10 qtrs)

Dividend Profile

Metric	Value
Annual dividend	$2.84/share
Current yield	~2.9% (at $98.61)
Consecutive years of increases	48 years

Technical Setup

Current Technicals (Feb 26, 2026)

Indicator	Value	Signal
Price	$98.61	Digesting post-Q3 gains
RSI (14)	36.3	🟡 Approaching Oversold — declining from ~58
SMA20	$100.61	Price -2.0% below SMA — very close
52-week range	$79.55 - $103.18	Trading near the top of range
YTD performance	~+22%	Significant outperformance YTD

Key Technical Levels

Level	Price	Notes
Immediate support	$93-95	Post-Q3 earnings gap-up base
Key support	$88-90	Previous resistance turned support; 200-DMA area
Strong support	$79-82	52-week low zone
Resistance 1	$100.61	SMA20 — just above
Resistance 2	$103.18	52-week high in data window
Long-term target	$108-117	Analyst consensus ($111.77 avg) to ATH recovery

Catalysts & Timing

Date	Event	Impact	Watch For
Mid-2026	MiniMed Diabetes spinoff/IPO	🟢🟢	Removes GLP-1 narrative; potential value unlock
Q4 FY26 Earnings (~May 2026)	Final quarter before FY26 close	🟢	Whether organic growth stays 5.5%+
FY2026-FY2027	Hugo US commercial placements	🟢	First disclosed Hugo placement/revenue data
Ongoing	PFA (Affera) market share vs BSX	🟢	Can MDT sustain majority share in new EP labs?

Entry Strategy

Entry Approach

Strategy	Details
Current	Watch — RSI approaching 35, but price still near 52wk high
Alert	$92 — entry zone bottom
Entry zone	$88 - $94 (~10-15% pullback)
RSI target for entry	RSI < 35 with price in $88-94 zone
Stop	$79 (-20% from entry zone)

Research Log

Date	Update
2026-02-22	Created deep dive. MDT not in stonks data system. Price ~$97.58 (market data). RSI ~58 (estimated). Q3 FY26 showed strongest enterprise growth in 10 quarters (+6.0% organic). PFA franchise +80%. GLP-1 headwind assessed as overblown. Hugo FDA cleared for urology Feb 2026. Conviction: Medium. Action: Watch, alert at $92.
2026-02-26	Fresh OHLC data now available. Price $98.61 (+1.1% vs prior). RSI fresh at 36.3 (was estimated ~58 — now clearly declining). SMA20 $100.61. RSI drop from ~58 to 36.3 shows post-Q3 digestion underway. -2.4% 7D, -2.0% 30D. Getting closer to entry zone ($88-94) but not there yet. Action: Watch, maintain $92 alert.

The Gold

Key Discoveries

Discovery	Implication
RSI dropped from ~58 to 36.3 in 4 days	Post-Q3 enthusiasm is cooling — approaching entry territory faster than expected
SMA20 $100.61, price $98.61 (only -2% gap)	MDT is right at its moving average — very clean technical level
52wk high $103.18 only 4.4% above current	Not much room above — upside is toward analyst targets ($108-117)
-2.4% 7D while RSI dropped 21+ pts	Price held relatively well while RSI normalized — constructive

Open Questions

What are the specific Hugo US placement numbers from the Q3 FY26 earnings call?
Is Affera genuinely winning majority share in new EP lab openings?
What multiple will MiniMed trade at post-spinoff?
Can MDT sustain 5.5-6% organic growth in FY2027 post-spinoff?
When does RSI reach the target entry zone (30-35) with price in $88-94?

Mistakes (If Applicable)

Mistake	Lesson
N/A — first deep dive, no capital deployed	If entering, wait for pullback to $88-94 — RSI at 36 is better than 58 but entry zone is still below current price

Sources

Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.